Modern Company began last night (Wednesday) in a trial of a vaccine adapted to the Lorient Omicron.
As part of the experiment, an Omicron-adapted vaccine will be given to two groups of participants: at one end they will receive two doses of Modern Vaccine, and in the other group participants who have already received two doses and another Booster dose of Modern.
Modern is planning to recruit about 300 participants for each group in this study to be performed at 24 medical centers in the US. Last night the vaccine was given to the first participant in the study. Pfizer also began a similar experiment and about two weeks ago Pfizer CEO said in March.
In addition, Modern has announced the results of another study which shows that the neutralizing antibodies against Omicron fade about a month after the booster dose.
The antibodies that neutralize the omicron strain faded 6.3 times the peak levels about a month after the booster dose, while the antibodies against the original strain of the virus faded more slowly - 2.3 times.
It shows that the booster dose of the vaccine increased 37-fold the levels of the neutralizing antibodies against Omicron compared to the level before the top dose (after two doses of vaccine).
"We are encouraged by the resistance of the antibody to omicron, six months after the currently approved booster dose of 50 mcg. To modernity.
"We will continue to share data with public health authorities to help them make evidence-based decisions about the best strategies to appoint an impetus against Corona," he said.
Were we wrong?
Fixed!
If you found an error in the article, we'll be happy for you to share it with us